Biotechnology startup Sonoma Biotherapeutics Inc. has signed a long-term lease to create a biomanufacturing and R&D facility at Unison Elliott Bay, a three-building life science and know-how campus underway in Seattle. JLL and Cushman & Wakefield represented the tenant.
“We’re happy there are such a lot of corporations within the Seattle space driving innovation to resolve massive challenges dealing with human well being. We’re additionally accustomed to navigating operations in thriving life science corridors given our footprint in Seattle and South San Francisco. Expertise, effectivity, and shut collaboration are key to maximizing our operations and we’re constructing a workforce and facility to assist this,” Sonoma Bio CTO Heidi Hagen instructed Industrial Property Govt.
Unison Elliott Bay is taking form because the redevelopment of three workplace buildings at 301, 401 and 501 Elliott Ave. W. into greater than 300,000 sq. ft of Class A workplace and life science house. Sonoma Bio will occupy 83,000 sq. ft on the campus’ third constructing and function anchor tenant for the property owned by Workplace Properties Earnings Belief. The RMR Group started the redevelopment mission in March, with completion anticipated in 2023.
READ ALSO: Adaptive Reuse or New Development? Issues for Life Sciences
After the revamp, the long run residence of Sonoma Bio will comprise 110,000 sq. ft of house, that includes high-end lab gear and infrastructure. Situated at 501 Elliott Ave. W. within the Uptown submarket, the ability is inside 2 miles of downtown Seattle and fewer than 2 miles from the 1.6-acre parcel the place BioMed Realty will develop a 616,000-square-foot life science and know-how complicated.
Cushman & Wakefield Managing Director Steve Lico and JLL Managing Director Kris Richey Curtis represented the tenant, whereas Tim Jones and Joe Gowan of JLL assisted RMR. Jones and Gowan additionally kind the mission’s leasing workforce.
Seattle’s life science scene
Seattle’s life science sector continues to flourish. The metro ranked among the many nation’s largest life science expertise and building clusters within the first quarter of 2022, with over $2.1 billion in funding, a emptiness charge of seven % and almost 50 % change in its six-year hire development, in keeping with a Cushman & Wakefield report. The development is fueled by growing demand, with obtainable house struggling to maintain up with the trade’s development.
Sonoma Bio CEO Jeff Bluestone acknowledged the ability’s potential on this increasing market. Bluestone mentioned, in a ready assertion, this heart will create highly-skilled scientific, engineering and manufacturing jobs within the Seattle space, making the most of the deep native capabilities and experience.
